文献速递神经肿瘤功能神经外科

司美替尼对1型神经纤维瘤病中弥漫性神经纤维瘤及视路胶质瘤的治疗效果

Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1.
PubMed 文献 · J Neurooncol · 2026-05-23

该研究为韩国II期开放标签试验的子分析,评估口服司美替尼治疗NF1相关弥漫性神经纤维瘤(NF1-DN)和视路胶质瘤(NF1-OPG)的疗效与安全性。88例NF1-PN患者中,25例(28%)合并NF1-DN,3例(3%)合并NF1-OPG。NF1-DN的确认部分缓解率(cPR)为24%,显著低于NF1-PN的88%(P<0.001)。司美替尼对NF1-DN有治疗潜力但反应率较低,NF1-OPG结果仅为探索性。

要点

  • 司美替尼治疗NF1-DN的cPR为24%,显著低于NF1-PN的88%。
  • NF1-DN中位最佳体积变化为-11.9%,而NF1-PN为-42.1%。
  • 3例NF1-OPG中1例达PR后CR但视力未改善,另2例维持SD。

核心结论

  • 司美替尼对NF1-DN显示出治疗潜力,但反应率低于NF1-PN。
  • NF1-OPG的发现仅为探索性,因病例数少,可为评估司美替尼对NF1相关病变的广泛效果提供额外临床背景。

研究设计与样本

  • 韩国II期开放标签试验的子分析,聚焦司美替尼对NF1-DN和NF1-OPG的非目标治疗效应。
  • 共88例NF1-PN患者(59例儿童和29例成人)接受口服司美替尼(20或25 mg/m²,或50 mg/次每12小时)至少2年(约26个周期,28天/周期)。

主要发现

  • 88例中NF1-DN 25例(28%),NF1-OPG 3例(3%)。
  • NF1-DN患者全部存在毁容,2例有疼痛;9例(36%)达到部分缓解(PR,单次评估肿瘤缩小≥20%)。
  • NF1-DN中位至PR时间为6个周期(范围6-12),中位至最佳反应时间为18个周期(范围6-26),中位体积变化为-11.9%(范围-55.4%至+36.3%)。
  • NF1-DN确认PR(cPR,PR持续>6个周期)6例(24%),稳定病(SD)9例(36%),进展病(PD)10例(40%)。
  • 配对比较中,NF1-DN的cPR显著低于NF1-PN(24% vs. 88%,P<0.001),中位最佳体积缩小也更小(-11.9% vs. -42.1%,P<0.001)。

临床怎么用

  • 司美替尼可用于NF1-DN的治疗,但需预期其反应率低于NF1-PN。
  • 对NF1-OPG的疗效证据有限,临床应用需个体化评估。

局限性

  • NF1-OPG病例数少(仅3例),结果仅为探索性。
  • 本研究为子分析,非目标治疗效应的评估可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Selumetinib is approved for the treatment of inoperable plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1). However, its efficacy in treating NF1-associated diffuse neurofibromas (NF1-DN) or optic pathway gliomas (NF1-OPG) remains unclear. We evaluated the efficacy and safety of selumetinib in these subgroups. METHODS: This was a sub-analysis of a Korean phase II open-label trial focusing on non-target treatment effects on NF1-DN and NF1-OPG. A total of 88 pediatric and adult patients with NF1-PN (59 children and 29 adults) in this trial had been treated for at least 2 years (~ 26 cycles, 28-day cycle) with oral selumetinib (20 or 25 mg/m², or 50 mg/dose every 12 h). Tumor volume, quality of life (QoL), and visual acuity were assessed. RESULTS: Among the 88 included patients, NF1-DN was diagnosed in 25 (28%), and NF1-OPG in 3 (3%). All NF1-DN patients exhibited disfigurement, two experienced pain, and a partial response (PR; ≥20% tumor reduction at a single time) was achieved in 9 of these cases (36%). The median time to PR was 6 cycles (range, 6-12), and the median time to best response was 18 cycles (range, 6-26), with a median volume change of - 11.9% (range, - 55.4% to + 36.3%). Confirmed PR (cPR; PR sustained for > 6 cycles) was observed in 6 NF1-DN patients (24%), stable disease (SD) was observed in 9 of these patients (36%), and progressive disease (PD) in 10 cases (40%). In a paired comparison, cPR was significantly lower for NF1-DN than for NF1-PN (24% vs. 88%, P < 0.001), and the median best volume reduction was also smaller (- 11.9% vs. -42.1%, P < 0.001). For the 3 NF1-OPG patients, visual impairment was present in all cases at baseline. One patient achieved PR at cycle 12 (- 36.1% from baseline) and complete response (CR) at cycle 26 but the visual acuity did not improve in this case. SD was maintained in the other two patients. Within these subgroups, QoL improved in 16 patients (57%) by cycle 26. No serious adverse events or treatment discontinuations were reported. CONCLUSIONS: Selumetinib shows therapeutic potential against NF1-DN, although with a lower response than that observed against NF1-PN. The NF1-OPG findings herein for this drug were exploratory only because of the small number of cases, but they may provide an additional clinical context for evaluating the broader effects of selumetinib across NF1-associated lesions. TRIAL REGISTRATION INFORMATION: KCT0003700, cris.nih.go.kr/cris/search/detailSearch.do/19,080, first submission March 4, 2019; first patient enrolled May 14, 2019.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hwang S, Kim PH, Kim H, et al. Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1. J Neurooncol. 2026. PMID: 42176046. doi:10.1007/s11060-026-05643-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。